National Eye Institute (NEI), part of the National Institutes of Health (NIH), has launched an ancillary study to the ongoing Age-Related Eye Disease Study 2 (AREDS2), to determine if home monitoring using the ForeseeHome AMD Monitor would lead to earlier detection of wet age-related macular degeneration (AMD).
NEI is the Federal government’s lead agency for vision research that leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness.
NEI said that the study compares ForeseeHome AMD Monitor detection with standard care, and result in better visual acuity following therapy at one year.
AREDS2, a nationwide study involving 4,000 individuals, determines whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from AMD. It is used by patients who are at moderate to high risk for developing age-related macular degeneration (AMD).
The ForeseeHome AMD Monitor is the ophthalmic device designed to provide ongoing monitoring of patients with AMD and can complete a brief exam on their ForeseeHome AMD Monitor in the comfort of their own home, transmitting data to the Notal Vision Data Monitoring Center.